 BETHESDA, Md., Sept. 09, 2021 GLOBE NEWSWIRE -- Gain Therapeutics, Inc. Nasdaq: GANX Gain, or the Company, a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Companys proprietary Structurally Targeted Allosteric Regulators STARs for GM1 Gangliosidosis and Morquio B Disease. 